RayBiotech Establishes Master Services Agreement With Major Biopharmaceutical Company
Published: May 23, 2012
NORCROSS, GA--(Marketwire - May 22, 2012) - RayBiotech, Inc. today announced that it has executed a master services agreement with a major West Coast-based biopharmaceutical company. Under the terms of the agreement, RayBiotech will provide custom services in the area of high-throughput preclinical research diagnostic testing. Specifically, RayBiotech will employ its antibody array diagnostics technologies to collect quantitative diagnostics information regarding key biochemical targets involved in human physiology and disease. Due to the sensitivity of the research, the partner company's identity is not being disclosed.
Commenting on the agreement, RayBiotech's President, COO and Co-founder, Rani Huang, said, "This is one of several master services agreements we have recently executed in the biopharma industry allowing us to exploit our antibody array diagnostics technologies in a services venue for the benefit of these partners. We are excited about this new services contract and expect to finalize several more similar agreements by year's end. This agreement reflects our recently announced strategic focus on further expansion of our growth and development through a broadening of our portfolio of products and services, as well as, increased customer activities on a global basis."
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001, RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
For More Information:
Rob Burgess, PhD
Director, Business Development
Email: Email Contact